Bêta-bloquants

<p>Applications (±)-2'-Methylpropranolol Hydrochloride, is an impurity of Nadolol (N201050), a β-Adrenergic blocker. Antihypertensive; antianginal.<br>References Dreyfuss, J., et al.: J. Clin. Pharmacol., 17, 300 (1977); Sibley, P.L., et al.: Toxicol. Appl. Pharmacol., 44, 379 (1978); Slusarek, L., et al.: Anal. Profiles Drug Subs., 9, 455 (1980)<br></p>

<p>Applications Rosuvastatin Methyl Ester is an impurity of Rosuvastatin (R700500) in the pharmaceutical dosage forms under forced degradation conditions.<br>References Lennernas, H., et al.: Clin. Pharmacokinet., 32, 403 (1997), Kivisto, K., et al.: Br. J. Clin. Pharmacol., 46, 49 (1998), Lan, K., et al.: J. Pharm. Biomed. Anal., 44, 540 (2007),<br></p>

<p>Applications (-)-Nebivolol intermediate.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>

<p>Applications A Labelled metabolite of Carvedilol which is a multiple-action, neurohormonal antagonist that is used in the treatment of hypertension.<br>References Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 958 (1998).<br></p>

<p>Applications A new known impurity of Carvedilol (C184625), published in Carvedilol USP monograph.<br></p>

<p>Applications Aprindine is a long-acting antiarrhythmic agent, effective when administered orally or intravenously in the treatment of ventricular arrhythmias of varying etiologies.<br>References Danilo, P. Jr., et al.: Am. Heart. J., 97, 119 (1979); Atarashi, H., et al.: Circulation. J., 66, 553 (2002);<br></p>

<p>Applications A metabolite of Propranolol.<br>References Otton, S., et al.: Br. J. Clin. Pharmacol., 30, 751 (1990), Fujita, S., et al.: J. Pharmacol. Exp. Ther., 264, 226 (1993), Bichara, N., et al.: Drug Metab. Dispos., 24, 112 (1996), Tasaki, T., et al.: J. Biochem., 123, 162 (1998),<br></p>

<p>Applications De(2,3-dihydroxy) Nadolol Hydrochloride is an impurity of Nadolol (N201050), a β-Adrenergic blocker. Antihypertensive; antianginal.<br>References Dreyfuss, J., et al.: J. Clin. Pharmacol., 17, 300 (1977); Sibley, P.L., et al.: Toxicol. Appl. Pharmacol., 44, 379 (1978); Slusarek, L., et al.: Anal. Profiles Drug Subs., 9, 455 (1980)<br></p>

<p>Applications N-Formyl Cardevilol is an impurity of Carvedilol (C184625).<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>

<p>Applications Bivalirudin 1-11 Fragment is an impurity of Bivalirudin, a direct thrombin inhibitor acting as an anticoagulant through inhibition of the enzyme thrombin.<br>References Bertrand, O. et al.: Am. J. Cardio., 110, 599 (2012); Patti, G. et al.: Am. J. Cardio., 110, 478 (2012)<br></p>

<p>Stability Hygroscopic<br>Applications Atorvastatin (A791750) impurity.<br>References Kearney, A.S., et al.: Pharm. Res., 10, 1461 (1993); Heinonen, T.M., et al.: Clin. Ther., 18, 853 (1996);<br></p>

<p>Applications Carvedilol (C184625) derivative.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br></p>

<p>Applications A metabolite of the antihypertensive agent, Labetalol (L096500).<br>References Gal, J., et al.: Res. Comm. Chem. Pathol. Pharmacol., 62, 3 (1988),<br></p>

<p>Applications (R)-Betaxolol is the R-isomer of Betaxolol (B328000), a cardioselective β1-adrenergic blocker (1,2,3). It is also an antihypertensive and antiglaucoma agent (4).<br>References (1) Bickel, M., et al.: J. Pharm. Pharmacol., 32, 669 (1980)(2) Cadigan, P.J., et al.: Br. J. Clin. Pharmacol., 9, 569 (1980) (3) Pathe, M., et al.: Therapie, 37, 75 (1982)(4) Panchal, V. S., et al.: J. Pharm. Sci. Pharmacol. 2, 21 (2015)<br></p>

<p>Applications Antihypertensive; antiarrhythmic (class II); antianginal; antiglaucoma agent.<br>References Wasson, et al.: J. Med. Chem., 15, 651 (1972), Franciosa, et al.: Clin. Pharmacol. Ther., 13, 138 (1972), Heel, R.C., et al.: Drugs, 17, 38 (1979), Rofman, B.A., et al.: Hypertension, 2, 643 (1980), Mazzo, D.J., et al.: Anal. Profiles Drug Subs., 16, 641 (1987),<br></p>

<p>Applications Hexobendine is used as vasodilator (coronary).<br>References Rdudolph, et al.: Arzneim.-Forsch., 20, 637 (1970), Kolassa, P., et al.: Biochem. Pharmacol., 20, 490 (1971), Zommer-Urbanska, S., et al.: Pharmazie, 40, 419 (1985),<br></p>

<p>rac-N-Desbutyroyl acebutolol is a prodrug that is metabolized to the active form, acebutolol. The metabolism of rac-N-desbutyroyl acebutolol is mediated through cytochrome P450 (CYP) enzymes, specifically CYP2D6. Rac-N-desbutyroyl acebutolol has been shown to inhibit the growth of bacteria in vitro and in vivo. It has also been shown to have therapeutic effects on diabetic patients with high levels of fatty acids in their blood. Rac-N-desbutyroyl acebutolol has also been found to be effective for the treatment of patients with polycarboxylic acid exposure and dna replication diseases.</p>

<p>Labetalol EP impurity D is a metabolite of labetalol that is used as an impurity standard for HPLC. This impurity has been identified in the drug product and also in the drug development process. Labetalol EP impurity D is one of many metabolites that can be formed by cytochrome P450 enzymes. Labetalol EP impurity D is a natural metabolite of labetalol, which can be found in the urine of humans and other mammals. It is also present in various plants and fungi, including mushrooms, lichens, yeast, and barley. Synthetic labetalol EP impurity D can also be produced by various chemical reactions.</p>